The Foundation for Research, Science and Technology (FRST) and New Zealand Trade and Enterprise (NZTE) asked LECG to identify the contribution that the human therapeutics discovery industry (the industry) brings to New Zealand.
FRST and NZTE asked LECG to calculate:
• The GDP that the industry generates for New Zealand.
• The employment that the industry generates for New Zealand.
• Better ways for the agencies involved to invest for the benefit of New Zealand.
In our report we also describe the qualitative benefits, and potential that the industry has for New Zealand, from our interviews with participants in the industry. We understand that the findings from this report will be used by FRST and NZTE to understand how best to support the industry. In particular, the findings will enable FRST and NZTE to determine how much they ‘invest’ and how they structure this investment in order to generate the greatest benefit to the industry and to New Zealand. Thus the report is also intended to give some indication of where on the value chain it might be wise to invest.
The focus of the brief is on companies involved in human therapeutics and excludes neutraceuticals, health supplements, bioengineering and medical devices.